CompletedPhase 2NCT00236041

Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)

Studying Sickle cell anemia

Last synced from ClinicalTrials.gov May 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Cephalon
Principal Investigator: John Messina, Pharm D
Cephalon, Inc.
Intervention: ACTIQ®(drug)
Enrollment: 38 target
Eligibility: 3-15 years · All sexes
Timeline: 2004 – 2006

Study locations (30)

Children's Hospital of Arkansas, Little Rock, Arkansas, United States
UCLA Pediatric Pain Program, Los Angeles, California, United States
Childrens Hospital of Orange, Orange, California, United States
Lucille Packard Childrens Hospital, Palo Alto, California, United States
Connecticut Childrens Medical Center, Hartford, Connecticut, United States
Children's National Medical Center, Washington D.C., District of Columbia, United States
Nemours Childrens Clinic, Jacksonville, Florida, United States
St. Joseph's Children's Hospital, Tampa, Florida, United States
Scottish Rite Children's Medical Center, Atlanta, Georgia, United States
Kapi'olani Medical Center, Honolulu, Hawaii, United States
Children's Memorial Center, Chicago, Illinois, United States
Children's Memorial Hospital, Chicago, Illinois, United States
University Hospitals of Iowa, Iowa City, Iowa, United States
Cardinal Glennon Children's Hospital, St Louis, Missouri, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00236041 on ClinicalTrials.gov

Other trials for Sickle cell anemia

Additional recruiting or active studies for the same condition.

See all trials for Sickle cell anemia →

← Back to all trials